Zeroing in on ROS1 rearrangements in non-small cell lung cancer.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 22859716.
- Also identified by DOI 10.1158/1078-0432.CCR-12-1812.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rimkunas and colleagues report on the development and validation of an immunohistochemical assay evaluating non-small cell lung cancers (NSCLC) for the presence of ROS1 fusions. The diagnostic was validated in a screen of 556 NSCLCs, identifying 9 (1.6%) tumors with oncogenic ROS1 rearrangements. These patients are candidates for ROS1-targeted therapies.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Carrier Proteins
- Lung Neoplasms
- Membrane Proteins
- Oncogene Proteins, Fusion
- Protein-Tyrosine Kinases
- Proto-Oncogene Proteins